← All trials
NCT05965193
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2023
- Primary completion
- Aug 30, 2025
- Completion date
- Oct 30, 2025
- First posted
- Jul 28, 2023
- Last posted
- Nov 7, 2023
- Enrollment
- 2218
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Anhui Medical UniversityCollaborator
- Linyi People's HospitalCollaborator
- Shandong Provincial HospitalCollaborator
- Xuzhou Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversityCollaborator
- Capital Medical UniversitySponsor investigator
- Nanchang UniversityCollaborator
- Soochow UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Government of ChinaCollaborator
- Jining NO.1 People 's HospitalCollaborator
- People's Hospital of RizhaoCollaborator
- Nantong UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Nanyang Central HospitalCollaborator
- Changsha Central HospitalCollaborator
- Zhumadian Central HospitalCollaborator
- Tianjin Huanhu HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.